001     163881
005     20240229123159.0
024 7 _ |2 doi
|a 10.1097/CMR.0000000000000482
024 7 _ |2 ISSN
|a 0960-8931
024 7 _ |2 ISSN
|a 1473-5636
024 7 _ |2 altmetric
|a altmetric:45174881
024 7 _ |2 pmid
|a pmid:30020195
037 _ _ |a DKFZ-2020-02115
082 _ _ |a 610
100 1 _ |a Brunssen, Alicia
|b 0
245 _ _ |a Long-term relative survival from melanoma in Germany 1997–2013
260 _ _ |a [s.l.]
|b Ovid
|c 2020
336 7 _ |2 DRIVER
|a article
336 7 _ |2 DataCite
|a Output Types/Journal article
336 7 _ |0 PUB:(DE-HGF)16
|2 PUB:(DE-HGF)
|a Journal Article
|b journal
|m journal
|s 1637147687_22468
336 7 _ |2 BibTeX
|a ARTICLE
336 7 _ |2 ORCID
|a JOURNAL_ARTICLE
336 7 _ |0 0
|2 EndNote
|a Journal Article
500 _ _ |a 2020 Aug;30(4):386-395
536 _ _ |0 G:(DE-HGF)POF3-313
|a 313 - Cancer risk factors and prevention (POF3-313)
|c POF3-313
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef
700 1 _ |0 P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09
|a Jansen, Lina
|b 1
|u dkfz
700 1 _ |a Eisemann, Nora
|b 2
700 1 _ |a Waldmann, Annika
|b 3
700 1 _ |0 P:(DE-He78)bf5409aed74a0923d9402c2c7ad620aa
|a Weberpals, Janick
|b 4
700 1 _ |a Kraywinkel, Klaus
|b 5
700 1 _ |a Eberle, Andrea
|b 6
700 1 _ |a Holleczek, Bernd
|b 7
700 1 _ |a Zeissig, Sylke R.
|b 8
700 1 _ |0 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
|a Brenner, Hermann
|b 9
|u dkfz
700 1 _ |a Katalinic, Alexander
|b 10
773 _ _ |0 PERI:(DE-600)2030780-9
|a 10.1097/CMR.0000000000000482
|g Vol. Publish Ahead of Print
|n 4
|p 386-395
|t Melanoma research
|v 30
|x 0960-8931
|y 2020
909 C O |o oai:inrepo02.dkfz.de:163881
|p VDB
910 1 _ |0 I:(DE-588b)2036810-0
|6 P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09
|a Deutsches Krebsforschungszentrum
|b 1
|k DKFZ
910 1 _ |0 I:(DE-588b)2036810-0
|6 P:(DE-He78)bf5409aed74a0923d9402c2c7ad620aa
|a Deutsches Krebsforschungszentrum
|b 4
|k DKFZ
910 1 _ |0 I:(DE-588b)2036810-0
|6 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
|a Deutsches Krebsforschungszentrum
|b 9
|k DKFZ
913 1 _ |0 G:(DE-HGF)POF3-313
|1 G:(DE-HGF)POF3-310
|2 G:(DE-HGF)POF3-300
|3 G:(DE-HGF)POF3
|4 G:(DE-HGF)POF
|a DE-HGF
|b Gesundheit
|l Krebsforschung
|v Cancer risk factors and prevention
|x 0
914 1 _ |y 2020
915 _ _ |0 StatID:(DE-HGF)0410
|2 StatID
|a Allianz-Lizenz
|d 2019-12-20
|w ger
915 _ _ |0 StatID:(DE-HGF)0420
|2 StatID
|a Nationallizenz
|d 2019-12-20
|w ger
915 _ _ |0 StatID:(DE-HGF)0100
|2 StatID
|a JCR
|b MELANOMA RES : 2018
|d 2019-12-20
915 _ _ |0 StatID:(DE-HGF)0200
|2 StatID
|a DBCoverage
|b SCOPUS
|d 2019-12-20
915 _ _ |0 StatID:(DE-HGF)0300
|2 StatID
|a DBCoverage
|b Medline
|d 2019-12-20
915 _ _ |0 StatID:(DE-HGF)0310
|2 StatID
|a DBCoverage
|b NCBI Molecular Biology Database
|d 2019-12-20
915 _ _ |0 StatID:(DE-HGF)0199
|2 StatID
|a DBCoverage
|b Clarivate Analytics Master Journal List
|d 2019-12-20
915 _ _ |0 StatID:(DE-HGF)1110
|2 StatID
|a DBCoverage
|b Current Contents - Clinical Medicine
|d 2019-12-20
915 _ _ |0 StatID:(DE-HGF)0110
|2 StatID
|a WoS
|b Science Citation Index
|d 2019-12-20
915 _ _ |0 StatID:(DE-HGF)0150
|2 StatID
|a DBCoverage
|b Web of Science Core Collection
|d 2019-12-20
915 _ _ |0 StatID:(DE-HGF)0111
|2 StatID
|a WoS
|b Science Citation Index Expanded
|d 2019-12-20
915 _ _ |0 StatID:(DE-HGF)0160
|2 StatID
|a DBCoverage
|b Essential Science Indicators
|d 2019-12-20
915 _ _ |0 StatID:(DE-HGF)1190
|2 StatID
|a DBCoverage
|b Biological Abstracts
|d 2019-12-20
915 _ _ |0 StatID:(DE-HGF)1030
|2 StatID
|a DBCoverage
|b Current Contents - Life Sciences
|d 2019-12-20
915 _ _ |0 StatID:(DE-HGF)1050
|2 StatID
|a DBCoverage
|b BIOSIS Previews
|d 2019-12-20
915 _ _ |0 StatID:(DE-HGF)9900
|2 StatID
|a IF < 5
|d 2019-12-20
920 1 _ |0 I:(DE-He78)C070-20160331
|k C070
|l C070 Klinische Epidemiologie und Alternf.
|x 0
920 1 _ |0 I:(DE-He78)C120-20160331
|k C120
|l Präventive Onkologie
|x 1
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C070-20160331
980 _ _ |a I:(DE-He78)C120-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21